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Annalisa Passariello1,3, Linda Cosenza1 and Riccardo Troncone1,2Abstract
Background: Amino acid-based formulas (Aaf) are increasingly used in children with cow’s milk allergy (CMA).
To be labeled hypoallergenic these formulas must demonstrate in clinical studies that they don’t provoke
reactions in 90% of subjects with confirmed CMA with 95% confidence when given in prospective randomized,
double-blind, placebo-controlled challenge (DBPCFC) trials. The majority of available safety data on Aaf derived
from patients with IgE-mediated CMA. Considering substantial differences in the immunologic mechanism and
clinical presentation of non-IgE-mediated CMA it’s important to investigate the hypoallergenicity of these
formulas also in these patients. We prospectively assessed the tolerance to a new commercially available Aaf in
children affected by IgE- or non-IgE-mediated CMA.
Methods: Consecutive patients affected by IgE- or non-IgE-mediated CMA, aged ≤ 4 years, were enrolled.
DBPCFC was carried out with increasing doses of the new Aaf (Sineall, Humana, Milan, Italy), using validated Aaf
as placebo. Faecal concentrations of calprotectin (FC) and eosinophilic cationic protein (ECP) were monitored.
Results: Sixty patients (44 male, 73.3%, median age 37, 95%CI 34.5–39.6 months, IgE-mediated CMA 29, 48.3%)
were enrolled. At the diagnosis clinical symptoms were gastrointestinal (46.6%), cutaneous (36.6%), respiratory
(23.3%), and systemic (10.0%). After DBPCFC with the new Aaf, no patient presented early or delayed clinical
reactions. Faecal concentration of calprotectin and of ECP remained stable after the exposure to the new Aaf.
Conclusions: The new Aaf is well tolerated in children with IgE- or non-IgE-mediated CMA, and it could be
used as a safe dietotherapy regimen for children with this condition.
Trial registration: The trial was registered in the ClinicalTrials.gov Protocol Registration System (ID number:
NCT01622426).
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Cow’s milk allergy (CMA) affects up to 3% of European
children [1]. The management of children with confirmed
CMA is based on complete avoidance of cow’s milk
proteins (CMP) and leaves the physician with several* Correspondence: berni@unina.it
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distribution, and reproduction in any mediumdietary options, none of which, given the prevalence,
spectrum and potential seriousness of the condition, can
be recommended to all patients [2]. In the absence of an
alternative to cow’s milk, the management of CMA is
based on the use of safe, affordable and nutritionally ad-
equate formulas. Extensively hydrolyzed cow’s milk protein
formulas (eHF), which are considered as safe for most chil-
dren with CMA, are still liable to contain residual peptides,
and hypersensitivity reactions may occur in infants allergic
to CMP [3]. Thus, the allergenicity of a specific product
must be addressed on an individual basis before
recommending a formula as a substitute for cow’s milk.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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children to soy [4-8]. Amino acid-based formulas (Aaf)
have been studied from safety and nutritional efficacy
perspectives [9-11]. These formulas have been proposed
for subjects highly sensitive to CMP and that cannot be
managed using eHF and for children with multiple food
allergies [3,11]. In these conditions Aaf are able to ef-
fectively cure allergic symptoms and to improve body
growth [12-14].
According to the American Academy of Pediatrics
(AAP) Subcommittee on Nutrition and Allergic Diseases
a hypoallergenic formula must be tested in infants and
children with hypersensitivity to CMP, with findings
verified by elimination-challenge tests under double-
blind, placebo-controlled conditions (DBPCFC). These
tests should show with at least 95% confidence that 90%
of allergic individuals will not react to the formula [11].
To control for possible false-negatives, a negative
DBPCFC should be followed by an open food challenge
(OFC) with the tested formula [15].
The possible subclinical intestinal mucosa inflamma-
tion in children with CMA in response to a challenge
with Aaf is largely unknown. Faecal calprotectin (FC) is
a widely accepted non-invasive inflammatory marker
able to measure even subclinical intestinal inflammation.
The FC concentration correlates with the level of muco-
sal inflammation, and increased FC levels have been
demonstrated in patients with food allergy [16-18]. Simi-
larly, eosinophilic cationic protein (ECP) has been
proposed for the diagnostic work up and follow-up of
children with food allergy, even during the oral food
challenge [19]. Starting from these considerations we
decided to include the evaluation of these non-invasive
markers to investigate possible subclinical intestinal in-
flammation induced by the study formula.
In this study we aimed to evaluate the tolerance to a
new commercially available Aaf containing nucleotides
in children with documented IgE- or non-IgE-mediated
CMA based on the criteria developed by the AAP’s Sub-
committee on Nutrition and Allergic Diseases [3].
Methods
Trial design
The study was conducted from October 2008 to June 2010.
The research protocol and informed consent form were
approved by the Ethics Committee of the University of
Naples “Federico II”. We evaluated patients (aged ≤ 4 years)
under good clinical control with a sure diagnosis of IgE- or
non-IgE-mediated CMA, confirmed by the result of
DBPCFC performed in the last 2 months. The vast majority
of these patients received the diagnosis during the first year
of life, but all subjects were still reacting to CMP. When
the last oral food challenge was performed the vast majority
(93.1%) of patients with IgE-mediated CMA reacted to thefirst 4 doses (from 0.1 to 3 ml of cow’s milk) and all patients
with non-IgE-mediated CMA reacted within 48 hours after
the procedure. We defined IgE- or non-IgE-mediated CMA
subjects according to the clinical history (acute or delayed
onset of symptoms after ingestion of CMP), the result of
oral food challenge (occurrence of typical symptoms within
2 or more than 2 hours after the administration of the last
dose), and the result of serum specific IgE, skin prick tests
(SPTs) and atopy patch tests (APTs).
The subjects were referred to 2 tertiary paediatric
gastroenterology and allergy Centers. We excluded
children with concomitant chronic systemic diseases,
congenital cardiac defects, active tuberculosis, auto-
immune diseases, immunodeficiency, chronic inflam-
matory bowel diseases, celiac disease, cystic fibrosis,
metabolic diseases, lactose intolerance, malignancy,
chronic pulmonary diseases, malformations of the
gastrointestinal tract, gastroesophageal reflux disease
non-food allergy-related, suspected eosinophilic gastro-
intestinal disorders. At the first evaluation, the clinical
history, information on food allergy and baseline clin-
ical conditions were assessed by 3 experienced paediat-
ric allergists in each Center and the child was invited to
participate in the study. At least one parent of each
subject provided written informed consent. Children
with atopic dermatitis were included if it was under
sufficient control to allow recognition of a positive re-
sponse to the challenge. Infants and children using a
beta-blocker within 12 hours of the challenge, and
short-acting, medium-acting, or long-acting anti-
histamines more than once within 3, 7, or 21 days of
DBPCFC, respectively, or oral steroids within 21 days
of DBPCFC were excluded from the study. Adverse
events were recorded throughout the study. The trial
was registered in the ClinicalTrials.gov Protocol Regis-
tration System (ID number: NCT01622426).Sample size
In a study with a binomial outcome (reaction versus
no reaction), the sample size can be determined by
calculating a binomial confidence interval (CI) for p,
the probability of having a reaction, as demonstrated
previously [20]. In the case of 0 observed reactions,
the upper 95% CI for p is less than 0.10 when the
sample size is 29 participants. Thus studying at least
29 participants and having none classified as positive
in the DBPCFC allows the conclusion that the study
provided 95% confidence that at least 90% of children
with confirmed CMA who ingest the tested formula
would have no reaction [3,21]. To explore the tole-
rance to a new Aaf either in children with IgE or
non-IgE-mediated CMA we planned to enroll at least
29 children per group.
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Food allergy screening tests
Measurement of serum specific IgE against CMP
(alpha-lactalbumin, ALA; beta-lactoglobulin, BLG; and
casein); SPTs with whole milk, CMP, placebo formula
(Neocate, Nutricia, Milan, Italy) and study formula
(Sineall, Humana, Milan, Italy); and APTs with whole
milk, placebo and study formula, were performed in
all patients.
Serum samples from patients were analyzed for spe-
cific IgE antibody titers against CMP using a commer-
cially available kit (CAP-RAST, Pharmacia Diagnostics
AB, Uppsala Sweden). The detection limit of the system
was 0.35 kU/L IgE. Subjects were deemed sensitized if
their specific IgE levels exceeded the detection limit.
Skin prick tests were performed using a 1-mm single
peak lancet (ALK, Copenhagen, Denmark), with hista-
mine dihydrochloride (10 mg/ml) and isotonic saline so-
lution (NaCl 0.9%) as positive and negative control,
respectively. Reactions were recorded on the basis of the
largest diameter (in millimetres) of the wheal and flare
at 15 min. The SPT results were considered “positive” if
the wheal was 3 mm or larger, without reaction of the
negative control.
Atopy patch tests were performed as previously
reported [22,23]. Briefly, we used 1 drop (50 μl) of fresh
milk put on filter paper and applied with adhesive tape
to the unaffected skin of the child’s back, using 12-mm
aluminium cups (Finn Chambers on Scan pore; Epitest
Ltd Oy, Tuusula, Finland). Isotonic saline solution was
the negative control. The occlusion time was 48 h and
results were read 20 min and 24 h after removal of the
cups. To exclude false positive reactions, we also tested
allergens in a 1:10 solution. Seventy-two hours after the
start of the test, reactions were classified as follows: -
negative; +/− doubtful: erythema only; + weak positive:
erythema, slight infiltration, papules; ++ strong positive:
erythema, infiltration, papules, little vesicles; +++ very
strong positive: erythema, large confluent vesicles in
bubbles. Children and their families were requested to
report any delayed skin reaction that was noticed after
this time. Irritant or doubtful reactions, including sharply
demarcated confluent erythema, or reactions confined to
margins without infiltration, were deemed negative.
Oral food challenge
All food challenges were performed as DBPC, and took
place in the outpatients clinic on 2 separate days with a
one week interval, as previously reported [24]. The
results were assessed simultaneously by 3 experienced
paediatric allergists in each Center. Randomization and
preparation of the challenges were performed by clinical
dieticians not directly involved in the study. We created
a computer-generated randomization list of participantnumbers indicating the order in which each study for-
mula was used in the DBPCFC.
Briefly, every 20 minutes, successive doses (0.1, 0.3, 1,
3, 10, 30 and 100 mL) of placebo (Neocate, Nutricia,
Milan, Italy) or of study formula (Sineall, Humana,
Milan, Italy) were administered. Full emergency equip-
ment and drugs (epinephrine, antihistamines, and
steroids) were at hand. Study subjects were scored for 9
items divided into 4 main categories: i. General (lowered
blood pressure plus tachycardia); ii. Skin (rash, urticaria/
angioedema); iii. Gastrointestinal (nausea/repeated
vomiting, crampy-like abdominal pain, diarrhea); and
iv. Respiratory (sneezing/itching, nasal congestion/
rhinorrhea, stridor deriving from upper airway obstruc-
tion or wheezing) on a 0- to 3-point scale (0, none; 1,
light; 2, moderate; and 3, severe). If at least 2 of the 3
physicians independently scored any item at level 3, or
2 (or more) items at level 2, the test result was
considered positive. Clinical symptoms occurring
within 2 h of administering the highest dose were
defined as “immediate reactions”, and those occurring
more than 2 h after the highest dose were defined as
“delayed reactions”. Patients were observed for 2 h after
the final dose, and then discharged. In the case of a
positive DBPCFC, at any testing dose, the patient
remained under observation until after symptoms were
resolved. If patients did not show any symptoms within
the first 24 hours, to assess long-term tolerance and re-
veal any false-negative results to the challenges, parents
were advised to administer to the patients one single
top dose (100 ml) of the tested formula (verum or
placebo) everyday at home for 7 days (7-day home
feeding period). Parents were invited to record daily:
the total amount of formula ingested by the subject; the
presence and severity of vomiting, diarrhea, rash, runny
nose, wheezing, or any other symptoms (rated as mild,
moderate, or excessive); and the number of bowel
movements. If any symptoms occurred during this
period, the subjects returned to the outpatient clinic on
the same day. The investigators completed a final
evaluation at the end of the 7-day home feeding period.
After 7-day home feeding period of verum or placebo ad-
ministration, the patients were examined and the parents
interviewed at the Centers. To rule out a false-negative
challenge result parents were asked to contact the Center
if any symptoms occurred in the following 7 days after the
DBPCFC procedures. The challenge was considered nega-
tive if the patient tolerated the entire challenge, including
the observation period. The composition of the study for-
mula is provided in Table 1.
Markers of intestinal mucosa inflammation
The faecal concentration of calprotectin and of ECP were
determined 24 hours before and 7 and 14 days after
Table 1 Composition of the study formula
100 g
powder
100 ml (15 g
powder +
90 ml water)
Energy kJ Kcal 2011 480 302 72
Carbohydrates g 58.2 8.7
Dextrins g 58.2 8.7
Protein g 12.2 1,8
Fat
Saturated fatty acid g 22.0 3.3
Monounsatured fatty acid g 7.8 1.2
Polyunsatured fatty acid g 9.7 1.5
Linoleic acid 18:2 g 4.5 0.7
Alpha-Linolenic acid 18:3 g 3.98 0.59
Linoleic acid : Linolenic acid g 0.5 0.076
8 8
Vitamins
Vitamin A μg 440 66
Vitamin D μg 9.6 1,4
Vitamin E mg 7.5 1,1
Vitamin K μg 23 3,5
Vitamin B1 mg 0.40 0,06
Vitamin B2 mg 0.64 0,1
Vitamin B6 mg 0.47 0,07
Vitamin B12 μg 0.97 0,15
Vitamin C mg 63 9,5
Niacin mg 3,8 0,57
Pantothenic acid mg 3,8 0,57
Folic acid μg 58 9
Biotin μg 9,5 1,4
Choline mg 98 15
Inositol mg 20 3
Carnitine mg 17.9 2,7
Taurine mg 28 4,2
Nucleotides
Cytidine-monophosphate mg 3.8 0,6
Uridine-monophosphate mg 4.5 0,7
Adenosine-monophosphate mg 6.9 1,0
Guanosine-monophosphate mg 1.3 0,2
Inosine monophosphate mg 2.5 0,4
Minerals
Sodium mg 165 25
Potassium mg 570 86
Chloride mg 308 46
Calcium mg 460 69
Phosphorus mg 295 44
Magnesium mg 42 6
Table 1 Composition of the study formula (Continued)
Trace elements
Iron mg 6.9 1,0
Copper μg 355 53
Zinc mg 7.1 1,1
Manganese mg 0.41 0,06
Iodine μg 99 15
Molybdenum μg 14.5 2,2
Fluorine μg 0.17 0,03
Selenium μg 9.0 1,4
Chrome mg 14.5 2,2
Osmolarity mOsm/l 275
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intestinal mucosa inflammation in response to study for-
mula. Stool samples were collected, stored at −20C and
analyzed at the end of the study by a researcher blinded
to the results of DBPCFC. Faecal calprotectin levels were
measured by a highly sensitive enzyme-linked immuno-
sorbent assay (ELISA, CalprestW, Eurospital, Italy), and
the results were expressed as μg/gr of stools. In a previ-
ous study we defined normal FC values for healthy
subjects (aged >12 months) within 100 μg/gr of stools
[16,25]. Eosinophilic cationic protein was analyzed by a
commercially available ELISA assay (ECP ELISA kit,
Dasit spa, Milan, Italy) and expressed as μg/g stools. We
defined normal mean stool ECP value for healthy
subjects (aged >12 months) as 0.88 μg/gr of faeces, 95%
CI 0.7–1.1 (data on file).
Statistical analysis
The SPSS software package (version 16.0 for Windows;
SPSS, Inc. Chicago, Ill) was used for statistical analysis.
The Pearson X2 test and the Fischer exact test were ap-
plied for categorical variables. Tests for equality of
means were used to examine continuous variables. For
all statistical tests, a 2-tailed P value of less than .05 was
considered significant.
Results
Of the 68 subjects assessed for eligibility, 60 patients (44
boys, 73.3%; median age 37, 95% CI 34.5–39.6 months)
completed the study. The study population included
47 CMA subjects with multiple food allergies to
hen’s egg, soy, peanut, wheat, and tree nut. The main
characteristics of the study population are reported
in Table 2.
At enrolment 28 out of the 29 children with IgE-
mediated CMA presented a positive SPT (28 to
whole milk, 96.5%; 20 to ALA, 68.9%; 16 to BLG,
55.1%; and 8 to casein, 27.5%). All these subjects
Table 2 Main demographic and clinical characteristics of
the study population
IgE mediated
cow’s milk allergy
n=29
Non-IgE-mediated
cow’s milk allergy
n=31
Sex, m (%) 20 (69) 24 (77.4)
Age, m (95% CI) 35 (31.0–38.9) 39 (35.7–42.3)
Volume of milk eliciting
positive challenge, ml
(95% CI)
6 (1.9–10.2) 144.4
Time of onset of reactions,
minutes (95 % CI)
48.1 (36.1–60.0) 1843.5
(1618.3–2068.8)
Concomitant multiple food
allergies, n (%)
24 (82.7) 23 (74.1)
•Hen’s egg, n (%) 16 (66.7) 5 (21.7)
•Soy, n (%) 3 (12.5) 11 (47.8)
•Peanut, n (%) 10 (41.7) 0
•Wheat, n (%) 5 (20.8) 8 (34.8)
•Tree nut, n (%) 3 (12.5) 0
Gastrointestinal symptoms,
n (%)
12 (41.4) 16 (51.6)
•Vomiting, n (%) 9 (31) 11 (35.5)
•Diarrhea, n (%) 4 (13.8) 20 (64.5)
•Hematochezia, n (%) 0 2 (6.4)
Cutaneous symptoms, n (%) 14 (48.3) 8 (2.6)
•Atopic dermatitis, n (%) 10 (71.4) 8 (100)
•Urticaria 4 (28.6) -
Respiratory symptoms, n (%) 14 (48.3) 0
Anaphylaxis, n (%) 6 (20.7) 0
Positive serum specific IgE
to CMP, n (%)
26 (89.6) 0
Positive skin prick test to
CMP, n (%)
28 (96.5) 0
Positive atopy patch test to
CMP, n (%)
0 27 (87)
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Specific IgE determinations for CMP were positive in 26
out of 29 patients with IgE-mediated CMA (89.6%).
Twenty-seven out of 31 children with non-IgE-mediated
CMA (87%) presented an APT positive to whole milk. One
patient presented a low positivity (+) for APT to placebo.
In all subjects with non-IgE-mediated CMA the APT to
study formula resulted negative.
The DBPCFC and open challenge resulted negative in
all subjects. In particular all patients were able to toler-
ate at least 100 ml of the study formula daily (mean
123 ml, range 105–143). No serious adverse events oc-
curred during the DBPCFC, open challenge, or extended
7-day feeding period of the study Aaf. As determined by
daily parental record, acceptance and tolerance of the
study Aaf were good.The optimal tolerance to the new Aaf was also
suggested by the result of FC and ECP determination.
All of the 60 subjects who completed the study had
negative FC and ECP results even before and after the
DBPCFC: FC (mean value before challenge 36.3 ±
22.1 μg/g vs mean values at 7 and 14 days after chal-
lenge 32.5 ± 23.8 μg/g and 33.5 ± 21.6 μg/g stools, respect-
ively), and ECP (mean value before challenge 0.93 ±
0.31 μg/g vs mean values at 7 and 14 days after challenge
0.92±0.27 μg/g and 0.90±0.30 μg/g stools, respectively)
remained stable after administration of the study formula.
Discussion
This is the first study on the tolerance to this new
commercially available Aaf in children with CMA. The
study provided 95% confidence that more than 90% of
subjects with CMA, many of whom had multiple food
allergies, tolerate the new Aaf, thus demonstrating the
hypoallergenicity of this formula. Skin prick tests and
APTs performed with the new Aaf resulted negative in
all study subjects. A peculiarity of our study is that we
evaluated also children with non-IgE-mediated CMA.
In this subgroup of patients tolerance was optimal.
This is an important point because the majority of
currently available data on Aaf has been obtained in
patients with IgE-mediated CMA. Considering the sub-
stantial differences in the immunologic mechanism and
clinical presentation of non-IgE-mediated CMA, we
believed of importance to explore the hypoallergenicity
of this formula also in these patients. Subjects with non-
IgE-mediated CMA frequently present with gastro-
intestinal symptoms [26]. All patients with these
characteristics tolerated the new Aaf. Of particular im-
portance in patients with gastrointestinal symptoms
related to non-IgE-mediated CMA could be the lower
osmolarity, compared to other Aafs on the market; and
the presence of nucleotides concentration similar to that
observed in human milk [27]. Extensive evidence
indicates that dietary sources of nucleotides are import-
ant to support immune function, small intestinal devel-
opment and function, and other processes of rapid cell
growth [27-29]. However, future clinical studies examin-
ing the effects of dietary nucleotides as single agents are
necessary to better understand the role that nucleotides
play in children with food allergy-related enteropathy as
well as to demonstrate the expected clinical benefits.
According to the optimal clinical tolerance to this new
Aaf we demonstrated that faecal levels of calprotectin
and ECP remained stable within the normal range dur-
ing the challenge.
As other studies conducted on Aafs we need further
studies to investigate the long term effects of this dietary
treatment on body growth and development, and on the
time of tolerance acquisition in children with CMA.
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We conclude that this new Aaf is well tolerated by chil-
dren with IgE- or non-IgE mediated CMA, and it could
be used as a safe dietotherapy regimen for children with
this condition.
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